Literature DB >> 19483707

Prasugrel.

Kurt Huber, Uma Yasothan, Bashar Hamad, Peter Kirkpatrick.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19483707     DOI： 10.1038/nrd2899

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  15 in total

Review 1.  Scientific and therapeutic advances in antiplatelet therapy.

Authors:  Deepak L Bhatt; Eric J Topol
Journal:  Nat Rev Drug Discov       Date:  2003-01       Impact factor: 84.694

2.  Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.

Authors:  Tomas Jernberg; Christopher D Payne; Kenneth J Winters; Christelle Darstein; John T Brandt; Joseph A Jakubowski; Hideo Naganuma; Agneta Siegbahn; Lars Wallentin
Journal:  Eur Heart J       Date:  2006-04-18       Impact factor: 29.983

3.  A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.

Authors:  John T Brandt; Christopher D Payne; Stephen D Wiviott; Govinda Weerakkody; Nagy A Farid; David S Small; Joseph A Jakubowski; Hideo Naganuma; Kenneth J Winters
Journal:  Am Heart J       Date:  2007-01       Impact factor: 4.749

Review 4.  Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4.

Authors:  Wei C Lau; Paul A Gurbel
Journal:  Pharm Res       Date:  2006-10-24       Impact factor: 4.200

5.  The disposition of prasugrel, a novel thienopyridine, in humans.

Authors:  Nagy A Farid; Richard L Smith; Todd A Gillespie; T James Rash; Patrick E Blair; Atsushi Kurihara; Mark J Goldberg
Journal:  Drug Metab Dispos       Date:  2007-04-02       Impact factor: 3.922

Review 6.  Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity.

Authors:  Yoichi Niitsu; Joseph A Jakubowski; Atsuhiro Sugidachi; Fumitoshi Asai
Journal:  Semin Thromb Hemost       Date:  2005-04       Impact factor: 4.180

7.  Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.

Authors:  Elliott M Antman; Stephen D Wiviott; Sabina A Murphy; Juri Voitk; Yonathan Hasin; Petr Widimsky; Harish Chandna; William Macias; Carolyn H McCabe; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2008-05-27       Impact factor: 24.094

8.  Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.

Authors:  Jean-Philippe Collet; Jean-Sébastien Hulot; Anna Pena; Eric Villard; Jean-Baptiste Esteve; Johanne Silvain; Laurent Payot; Delphine Brugier; Guillaume Cayla; Farzin Beygui; Gilbert Bensimon; Christian Funck-Brentano; Gilles Montalescot
Journal:  Lancet       Date:  2008-12-26       Impact factor: 79.321

9.  Cytochrome p-450 polymorphisms and response to clopidogrel.

Authors:  Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Richard D Hockett; John T Brandt; Joseph R Walker; Elliott M Antman; William Macias; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

10.  Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.

Authors:  P Michael Ho; Thomas M Maddox; Li Wang; Stephan D Fihn; Robert L Jesse; Eric D Peterson; John S Rumsfeld
Journal:  JAMA       Date:  2009-03-04       Impact factor: 56.272
View more
  6 in total

1.  Fresh from the pipeline. Ticagrelor.

Authors:  Kurt Huber; Bashar Hamad; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

Review 2.  Antithrombotic therapy in patients with acute coronary syndrome and diabetes mellitus.

Authors:  S Farhan; I Tentzeris; M K Freynhofer; B Vogel; K Huber
Journal:  Herz       Date:  2012-05       Impact factor: 1.443

3.  An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention.

Authors:  Julio Marchini; David Morrow; Frederic Resnic; Andre Manica; James Kirshenbaum; Christopher Cannon; Kevin Croce
Journal:  Crit Pathw Cardiol       Date:  2010-12

4.  Bis(2-amino-5-benzyl-3-eth-oxy-carbonyl-4,5,6,7-tetra-hydro-thieno[3,2-c]pyridin-5-ium) bis-(4-meth-oxy-phen-yl)di-phos-phon-ate.

Authors:  Mehmet Akkurt; Joel T Mague; Shaaban K Mohamed; Sabry H H Younes; Mustafa R Albayati
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2014-02-22

5.  Crystal structure of (4-meth-oxy-phen-yl)[(4-meth-oxy-phen-yl)phospho-nato]dioxidophosphate(1-) 2-amino-6-benzyl-3-eth-oxy-carbon-yl-4,5,6,7-tetra-hydro-thieno[2,3-c]pyridin-6-ium.

Authors:  Joel T Mague; Shaaban K Mohamed; Mehmet Akkurt; Sabry H H Younes; Essam K Ahmed; Mustafa R Albayati
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2015-11-28

6.  Pharmacogenomic considerations for antiplatelet agents: the era of precision medicine in stroke prevention and neurointerventional practice.

Authors:  Phillip A Bonney; Benjamin Yim; Waleed Brinjikji; Brian P Walcott
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-04-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.